Trial reportHepatology (Baltimore, Md.)2020
A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection.
Trial report in Hepatology (Baltimore, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Psychosocial therapy improves outcomes for alcohol use disorder in people with chronic liver disease: A systematic review and meta-analysis.Hepatology communications · 2025Pooled it
- Efficacy of psychosocial interventions to reduce alcohol use in comorbid alcohol use disorder and alcohol-related liver disease: a systematic review of randomized controlled trials.Alcohol and alcoholism (Oxford, Oxfordshire) · 2023Pooled it
- Simultaneous Management of Alcohol Use Disorder and Liver Disease: A Systematic Review and Meta-analysis.Journal of addiction medicinePooled it
- Changes in alcohol use during hepatitis C treatment in persons who inject drugs.Journal of viral hepatitis · 2022Trial
- A Randomized Trial Comparing Brief Advice and Motivational Interviewing for Persons with HIV-HCV Co-infection Who Drink Alcohol.AIDS and behavior · 2021Trial
- Linkage and alcohol use outcomes of a screening, brief intervention, and referral to treatment (SBIRT) program for alcohol-related liver disease: A retrospective cohort study from India.Indian journal of psychiatry · 2026Article
- Implementation of Mobile-Based Programs for Alcohol Cessation in the Treatment of Alcohol-associated Liver Disease: Protocol for a Type 1 Hybrid Implementation-Effectiveness Trial.JMIR research protocols · 2026Article
- Perceived disabling physical pain and suicidal ideation in aging people living with HIV cured of hepatitis C: A multi-center survey in France (ANRS CO13 HEPAVIH).HIV medicine · 2026Article
- Integrated approaches to reduce alcohol use in people with liver disease: a scoping review and quantitative analysis.Alcohol and alcoholism (Oxford, Oxfordshire) · 2025Article
- Alcohol-associated liver disease: Natural history, management and novel targeted therapies.Clinical and molecular hepatology · 2025Review
- Alcohol-related liver disease.Gastroenterology report · 2025Review
- Treatment of Alcohol Use Disorder: Behavioral and Pharmacologic Therapies.Clinics in liver disease · 2024Review
- Psychological processes and alcohol reduction in patients with chronic hepatitis C: Results from the HepART trial.Alcohol, clinical & experimental research · 2024Article
- Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action.Addiction science & clinical practice · 2024Review
- Low-Burden Universal Substance Use Screening in a Primary Care Clinic to Lower Implementation Barriers.The journal of behavioral health services & research · 2023Article
- Alcohol consumption upon direct-acting antiviral therapy for hepatitis C among persons with human immunodeficiency virus in the United States.Drug and alcohol dependence · 2022Article
- Hepatitis C virus: A critical approach to who really needs treatment.World journal of hepatology · 2022Review
- Reduced Alcohol Use Is Sustained in Patients Provided Alcohol-Related Counseling During Direct-Acting Antiviral Therapy for Hepatitis C.Digestive diseases and sciences · 2021Article
- Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression and drinking motives.Journal of viral hepatitis · 2021Article
- Role of ALDH2 in Hepatic Disorders: Gene Polymorphism and Disease Pathogenesis.Journal of clinical and translational hepatology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsHepatitis C virus (HCV) and alcohol use are patient risk factors for accelerated fibrosis progression, yet few randomized controlled trials have tested clinic-based alcohol interventions. APPROACH AND
resultsA total of 181 patients with HCV and qualifying alcohol screener scores at three liver center settings were randomly assigned to the following: (1) medical provider-delivered Screening, Brief Intervention, and Referral to Treatment (SBIRT), including motivational interviewing counseling and referral out for alcohol treatment (SBIRT-only), or (2) SBIRT plus 6 months of integrated colocated alcohol therapy (SBIRT + Alcohol Treatment). The timeline followback method was used to assess alcohol use at baseline and 3, 6, and 12 months. Coprimary outcomes were alcohol abstinence at 6 months and heavy drinking days between 6 and 12 months. Secondary outcomes included grams of alcohol consumed per week at 6 months. Mean therapy hours across 6 months were 8.8 for SBIRT-only and 10.1 for SBIRT + Alcohol Treatment participants. The proportion of participants exhibiting full alcohol abstinence increased from baseline to 3, 6, and 12 months in both treatment arms, but no significant differences were found between arms (baseline to 6 months, 7.1% to 20.5% for SBIRT-only; 4.2% to 23.3% for SBIRT + Alcohol Treatment; P = 0.70). Proportions of participants with any heavy drinking days decreased in both groups at 6 months but did not significantly differ between the SBIRT-only (87.5% to 26.7%) and SBIRT + Alcohol Treatment (85.7% to 42.1%) arms (P = 0.30). Although both arms reduced average grams of alcohol consumed per week from baseline to 6 and 12 months, between-treatment effects were not significant.
conclusionsPatients with current or prior HCV infection will engage in alcohol treatment when encouraged by liver medical providers. Liver clinics should consider implementing provider-delivered SBIRT and tailored alcohol treatment referrals as part of the standard of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.